We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Avacta, the developer of Affimer® biotherapeutics and reagents, has begun work with the UK government’s CONDOR program to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry (BAMS™) laboratory assay developed ...